Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) shot up 3.6% on Monday . The company traded as high as $1.81 and last traded at $1.75. 100,206 shares changed hands during trading, a decline of 93% from the average session volume of 1,520,231 shares. The stock had previously closed at $1.69.
Wall Street Analyst Weigh In
A number of research firms have weighed in on CTOR. Citigroup lowered Citius Oncology to a "hold" rating in a research note on Friday, May 23rd. Wall Street Zen upgraded Citius Oncology to a "hold" rating in a research note on Saturday, July 26th. Finally, Maxim Group lowered Citius Oncology from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd.
Check Out Our Latest Stock Report on CTOR
Citius Oncology Stock Up 3.6%
The stock has a 50 day simple moving average of $2.44 and a two-hundred day simple moving average of $1.44. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.02 and a current ratio of 0.35.
Institutional Investors Weigh In On Citius Oncology
A number of institutional investors have recently modified their holdings of CTOR. Citadel Advisors LLC acquired a new stake in shares of Citius Oncology during the 4th quarter valued at about $26,000. Bank of America Corp DE grew its position in shares of Citius Oncology by 5,256.9% during the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company's stock valued at $37,000 after acquiring an additional 8,411 shares during the period. Arkadios Wealth Advisors acquired a new stake in shares of Citius Oncology during the 2nd quarter valued at about $51,000. Geode Capital Management LLC grew its position in shares of Citius Oncology by 179.0% during the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company's stock valued at $249,000 after acquiring an additional 36,758 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Citius Oncology during the 2nd quarter valued at about $465,000. 70.52% of the stock is currently owned by institutional investors and hedge funds.
About Citius Oncology
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access